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Intellectual property (IP) — patent, copyright, trademark and industrial 
design — is the foundation for a thriving consumer society and a 
significant driver for economic growth. Most importantly for right now, it 
is the engine to help the globe out of the coronavirus pandemic. To fight 
, there is an urgent need for personal protection equipment 
for medical professionals, the deployment of safe and reliable testing, and 
the research, testing and rollout of a vaccine. To effectively do all that, 
governments around the world need to intervene to lessen IP restrictions 
in the short term and control spiraling prices.  
With the shortage of CPAP hoods — to provide patients with oxygen — 
Italian doctors have been , violating the 
patent on the machines. Medicines need to be replicated en masse to 
fight the pandemic. Data exclusivity among researchers is slowing down 
the development of vaccines to ward off COVID-19. We need to relax IP 
rules to allow companies — small, medium and large, domestic and 
foreign — to contribute to these efforts.  Price controls may be called for.  
First, about the machines such as ventilators: A patentable invention 
grants its inventor certain exclusive rights. These rights include 
preventing non-authorized making, using, offering for sale, or importing 
for these purposes patented products or processes. A process patent 
protects the method by which the product is made. Now is not the time to 
prosecute these patent infringement claims. The use of the 
 in the United States and legislative solutions in other 
countries is one step. Governments also should be acquiring the rights to 
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critical medical products and services to fight the coronavirus. We can 
divide up the spoils later.
Second, concerning much-needed medicine, we should consider 
compulsory licensing. The laws of many countries authorize granting a 
compulsory license for the services of the government for national 
defense, emergency, or public non-commercial use. However, certain 
conditions, sometimes onerous and time-consuming, must be met before 
a compulsory license will be granted. The interested party should first try 
to amicably negotiate a license with the patentee. In addition, the 
compulsory license shall be granted principally to supply the national 
market. When granted, a compulsory license should be non-exclusive. If 
the circumstances leading to the granting of a compulsory license cease 
to exist, compulsory license should be suspended.  
Compulsory licensing can be used for COVID-19 tests and drugs to treat 
the disease. Issuing a compulsory license for drugs can fall under 
emergency circumstances exceptions in national laws. The use of such 
licenses prevents patent holders from using their rights in a manner that 
might restrict trade. In response to COVID-19, Canada 
 to speed the process of issuing compulsory licenses for 
medical products. And it does not have to be limited to medicines: Brazil 
suspended compulsory licensing for tubes and syringes. Rather than 
undergoing the usual process of haggling with a company over terms, 
these governments can simply issue a license and negotiate 
compensation later.
Third, data exclusivity is another area for quick action, because it can 
delay the introduction of generic competition for existing drugs. It is high 
time for pharmaceutical companies, scientists and medical associations 
to share data and transfer technology to treat COVID-19. Generic drug 
applications can be encouraged even if data submitted by a generic 
producer is based on data originally compiled by the brand-name 
producer. Extreme health issues can and should justify such extreme 
measures that violate IP rights. 
Lastly, there is a need for price control measures. Over the years, 
 dramatically. Non-contagious diseases such as 
heart diseases, cancers and diabetes, are major causes of death. Now, 
with the COVID-19 outbreak, we are witnessing the  of 
certain essential drugs in hospitals, which could lower per capita 
consumption of medicines. Several factors could contribute to an 
increase in prices of drugs, including inflation, currency values and high 
levels of patent protection. 
Higher drug prices would put a strain on the public health system, and for 
those Americans without health insurance, higher prices would require 
significant out-of-pocket expenditure. During these difficult times, the 
government could rely on some forms of price controls on drugs. For 
example, the government can establish reference prices for drugs. 
Reference prices are set at only slightly higher levels than prices for 
generic drugs in order to encourage competition.
In addition, the government could create a cap on drug prices deemed 
excessive; drug prices should reflect a reasonable monetary return for the 
manufacturer on the cost of production. Moreover, the government can 
subsidize drugs indirectly by reimbursing patients who pay up front. 
Although these price controls yield lower revenue for drug firms and 
medical device manufacturers by preventing them from charging market-
based prices, they address wider health policy considerations such as 
access and affordability. 
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We must recognize that corporations, and the scientists who work at 
them, are economic actors who want and deserve to be compensated for 
their efforts, investments, research and products that emerge. For 
example, it is estimated that the , including 
the costs of capital and failed research and development efforts, hovers 
at $400 million. Without strong protection for these innovations, there 
will be no economic justification for investment. 
But this is a different time — this is a global emergency. Millions of people 
will be infected with COVID-19 and require treatment, and hundreds of 
millions more need to be tested. And more than 7 billion people may need 
to be vaccinated once we find a way to protect humanity from this horrid 
pandemic. The niceties of IP law should not get in the way of our 
countries fighting it.  
James M. Cooper is a professor of law at California Western School of Law 
in San Diego. He is a former member of the U.S. government delegation to 
the World Intellectual Property Organization Advisory Committee on 
Enforcement.  
Bashar Malkawi is director of knowledge management at the H.H. Dubai’s 
Ruler Court, Government of Dubai, Legal Affairs Department and a former 
dean of the University of Sharjah in the United Arab Emirates.  
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